Immuno-Oncology | Specialty

Dr. Whitman on the Role of Pembrolizumab in Melanoma

March 15th 2018

Eric Whitman, MD, surgeon, Atlantic Health System, discusses the role of pembrolizumab (Keytruda) in the treatment of patients with melanoma.

Dr. Brahmer Discusses Second-Line Pembrolizumab in NSCLC

March 15th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses second-line pembrolizumab (Keytruda) in non–small cell lung cancer.

Guidelines Clarify Management of Immune-Related AEs in Lung Cancer

March 14th 2018

Heather Greene, NP, discusses the safety profile for patients with lung cancer receiving immunotherapy, and the importance for reporting immune-related adverse events.

Chemotherapy May Be Vital to Long-Term Immunotherapy Efficacy in Bladder Cancer

March 14th 2018

Parminder Singh, MD, discusses the potential of immunotherapy, the importance of sequencing to avoid disease progression, and the use of chemotherapy and radiation therapy to reach an unmet need in muscle-invasive bladder cancer.

FDA Grants Pembrolizumab Priority Review in Cervical Cancer

March 13th 2018

The FDA has granted a priority review to pembrolizumab (Keytruda) for the treatment of advanced cervical cancer with disease progression on or after chemotherapy.

Locally Advanced NSCLC: Audience Q&A

March 13th 2018

Promising Developments in Locally Advanced NSCLC

March 13th 2018

Improving Care in Locally Advanced NSCLC

March 13th 2018

Tips for Managing NSCLC Patients on Durvalumab Therapy

March 13th 2018

NSCLC: Consolidation Immunotherapy in Practice

March 13th 2018

Chemotherapy Choices in the PACIFIC Trial

March 13th 2018

PACIFIC Trial: A Game Changer in Unresectable LA NSCLC

March 13th 2018

Locally Advanced NSCLC: Treatment Overview

March 13th 2018

Key Considerations in the Management of Stage 3 NSCLC

March 13th 2018

Locally Advanced NSCLC: Treatment Goals and Challenges

March 13th 2018

New Paradigms for Treatment of Locally Advanced NSCLC

March 13th 2018

Dr. Gupta on the Role of Surgery in Bladder Cancer

March 12th 2018

Amit Gupta, MD, urologic oncologist, Department of Surgery, Cedars-Sinai Medical Center, discusses how the use of immunotherapy agents is altering the role of surgery in bladder cancer and the need for Bacillus Calmette-Guérin (BCG) alternatives.

Emerging Advances for Immunotherapy in Urothelial Cancer

March 9th 2018

Promise of DNA Vaccines in Bladder Cancer

March 9th 2018

Improving Responses to Immunotherapy in Bladder Cancer

March 9th 2018